Common-Size Income Statement
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Vertex Pharmaceuticals Inc., common-size consolidated income statement
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Income (loss) from operations | The net result for the period of deducting operating expenses from operating revenues. | Vertex Pharmaceuticals Inc. income (loss) from operations as a percentage of revenues decreased from 2022 to 2023 and from 2023 to 2024. |
| Income before provision for income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Vertex Pharmaceuticals Inc. income before provision for income taxes as a percentage of revenues decreased from 2022 to 2023 and from 2023 to 2024. |
| Net income (loss) | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Vertex Pharmaceuticals Inc. net income (loss) as a percentage of revenues decreased from 2022 to 2023 and from 2023 to 2024. |